Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 14/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.33 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4119742 | 0.92 | ADORA3 (0.35) | ADORA2AADORA3HRH4HRH3DNMT1 | |
| Trifluoroacetic Acid SCHEMBL4124585 | 0.89 | ADORA2A (0.44) | ADORA2AADORA3 | |
| Trifluoroacetic Acid SCHEMBL2091169 | 0.88 | ADORA2A (0.41) | ADORA2AADORA3HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL1402083 | 0.88 | ADORA2A (0.41) | ADORA2AADORA3HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL1402051 | 0.87 | ADORA2A (0.48) | ADORA2AADORA3HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL241327 | 0.87 | ADORA2A (0.43) | ADORA2AADORA3HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL4123164 | 0.87 | ADORA2A (0.44) | ADORA2AADORA3HRH4HRH3DNMT1 | |
| SCHEMBL4119749 | 0.86 | ADORA3 (0.34) | ADORA2AADORA3DNMT1DNMT3B | |
| Trifluoroacetic Acid SCHEMBL241434 | 0.85 | ADORA2A (0.53) | ADORA2AADORA3HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL1402085 | 0.85 | ADORA2A (0.48) | ADORA2AADORA3HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099214-A1 | Organic Compounds | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099214-A1 | Organic Compounds | CYP3A43, OXER1, OPRM1 | ADORA2A 2082/4885ADORA3 554/4885HRH4 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.